When Kamala Harris was California’s top prosecutor, she was concerned that mergers among hospitals, physician groups, and health insurers could thwart competition and lead to higher prices for patients.
Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines for neuropsychiatric conditions, for $14 billion. The deal values Karuna